Introduction
One of the major concerns arising in cancer chemotherapy is multidrug resistance which is caused, at least in part, by expression of P-glycoprotein (P-gp). The MDR-1 gene encodes P-gp which is an energy-dependent efflux pump and acts as a transporter of various structurally unrelated compounds such as actinomycin D, adriamycin, colchicine and vinca alkaloids. [1] [2] [3] The gene regulation of the MDR-1 remains a controversial issue. The genomic structure of the 5Ј-flanking region of the MDR-1 gene was determined and the region upstream from the major transcription start site was confirmed to have promoter activity. 4 This region contains putative CAAT-and GC-boxes, but lacks the TATA-box which is a common signal for eukaryotic mRNA transcription by RNA polymerase II. 4 Cornwell et al, 5 using a luciferase assay, reported that the -110 GC-box and -50 GC-box function as transcriptional 'repressor' and 'enhancer' binding sites, respectively. 5 SP-1 (specificity protein-1) and EGR-1 (early growth response gene-1) have been shown to act as transcriptional activators for the MDR-1 gene promoter. 5, 6 In higher-order eukaryotic cells, DNA is methylated only at cytosines located 5Ј to guanosine in the CpG dinucleotide. 7 This modification has important regulatory effects on gene expression, especially when involving CpG-rich areas known as CpG islands, located in the promoter regions of many genes. 8, 9 Aberrant methylation of CpG islands, which are nor- mally unmethylated, has frequently been documented in immortalized and transformed cells 10 and has been associated with transcriptional inactivation of defined tumor suppresser genes in human cancers. [11] [12] [13] [14] For example, frequent methylation of the p15 gene promoter was shown to induce its down-regulation in leukemias. 15, 16 Hypermethylation in the promoter region of the estrogen receptor was also shown to lead to its down-regulation in breast cancers. 17 A similar mechanism might act in MDR-1 gene regulation.
In the present investigation, we analyzed the methylation pattern of -110 and -50 GC-boxes in the MDR-1 promoter region in K562 and K562/ADM (adriamycin-resistant K562) cells. We also assessed the effect of 5-Aza-2Ј-deoxycytidine (DAC), an inhibitor of DNA methyltransferase, on MDR-1 gene expression in K562/ADM cells. Our data suggest that MDR-1 gene expression is associated with methylation status at the repressor binding site (-110 GC-box).
Materials and methods
DAC and sodium bisulfite were purchased from Sigma Chemical (St Louis, MO, USA), ISOGEN from Nippon Gene (Tokyo, Japan) and antibody against P-gp (UIC2) for flow cytometric analysis from Coulter (Tokyo, Japan). All other chemicals were obtained from standard sources. K562 and K562/ADM cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, penicillin (50 U/ml), streptomycin (50 g/ml) and 0.2% (w/v) sodium bicarbonate in 5% CO 2 /95% humidified air. The cells were routinely passaged with medium changes twice a week. K562/ADM cells were cultured in the presence of 300 ng/ml adriamycin for 3 days every 2 weeks.
Analysis of methylation status in promoter region of MDR-1 gene
Genomic DNA was prepared from K562 or K562/ADM cells by using ISOGEN solution according to the manufacturer's instructions. DNA methylation patterns in the CpG island of the MDR-1 gene promoter were determined by chemical modification; unmethylated cytosines were changed to uracil by sodium bisulfite treatment, while methylated cytosines were not. Two micrograms of DNA were denatured with NaOH and modified by sodium bisulfite. DNA was then purified using Wizard DNA purification resin (Promega, Lake Placid, NY, USA), again treated with NaOH, precipitated with ethanol and resuspended in water. Subsequently, PCR was performed using the primer sets designed to amplify both the methylated and the modified unmethylated DNA sequence. The primer pair for this reaction was 5Ј-GGTGATATA-Leukemia GAATTGGAGAGG-3Ј and 5Ј-CCTCAAAAAACCCTTCTCC-3Ј which amplified the region including the -110 GC and -50 GC-boxes. PCR products were purified using Wizard PCR purification resin, ligated into pGEM-T Easy Vector (Promega) followed by a transformation protocol using DH5␣ as competent cells. After plasmid isolation, 20 clones were obtained and subjected to sequence analysis with an ABI automated DNA sequencer using a dye termination kit (ABI, Foster City, CA, USA). Based on these data, we made primer pairs for methylation-specific PCR analysis (MSP). Primer sequences for the -110 GC-box of MDR-1 were 5Ј-TATTTAGTTAATT CGGGTCG-3Ј (upper primer)/5Ј-TAAACTCAAACTTCCTA-TAAC-3Ј (lower primer) for the methylated allele and 5Ј-TTTAGTTAATTTGGGTTGGG-3Ј (upper)/5Ј-TAAACTCAAA CTTCCTATAAC-3Ј (lower) for the unmethylated allele. The annealing temperature was 51°C. The expected PCR product size was 125 bp. Primers for the -50 GC-box were 5Ј-GTTGGGTAGGAATAGCGTC-3Ј (upper)/5Ј-CCTCAAAAAA CCCTTCTCC-3Ј (lower) for the methylated allele and 5Ј-TAG-GAATAGTGTTGGGGTG-3Ј (upper)/5Ј-CCTCAAAAAACCC TTCTCC-3Ј (lower) for the unmethylated allele. The annealing temperature was 51°C. The predicted size of the amplified product was 306 bp. The PCR products were visualized, after 2.0% agarose gel electrophoresis, by ethidium bromide staining.
Flow cytometric analysis of MDR-1 in K562/ADM cells treated with DAC
K562/ADM and K562 cells were treated with or without 5.0 M DAC for 4 days. DAC was easily inactivated in the culture medium, such that supplementation every 24 h was required. The samples were then divided into two portions; one for flow cytometric analysis and the other for Northern blot analysis. The flow cytometric procedure was as follows. K562/ADM and K562 cells were washed once with PBS and resuspended in 200 l of binding buffer (10 mm HEPES, pH 7.4, 140 mm NaCl, 2.5 mm CaCl 2 ). Samples were then incubated with PE-conjugated UIC2, anti-P-gp antibody (Coulter, Tokyo, Japan) at room temperature in the dark for 30 min. After a brief centrifugation, cells were resuspended in 2000 l of binding buffer and subjected to flow cytometric analysis using EPICS XL System II (Coulter).
Northern blot analysis of MDR-1 in K562/ADM cells treated with DAC
Total cellular RNAs were isolated from K562/ADM and K562 cells, using ISOGEN solutions. Seven micrograms of total RNA was subjected to electrophoresis in 1.0% agarose-formaldehyde gels and transferred on to Hybond N + nylon filters (Amersham Life Science Technology, Tokyo, Japan) by capillary blotting in 20 × SSC (1 × SSC; 150 mm NaCl, 12.5 mm sodium citrate, pH 7.0). The filter was baked at 80°C for 3 h and prehybridized at 42°C for 1 h in 50% formamide, 5 × Denhardt's, 5 × SSC, 0.1% SDS and 100 g/ml sheared salmon sperm DNA. For probe preparation, a partial cDNA for human P-gp was amplified by RT-PCR using template cDNA and oligonucleotide primers (5Ј-GCTCAAAGAAGCA-GAGGCCG-3Ј and 5Ј-AGCTCCCCAACATCGTGCAC-3Ј). The amplified products were purified using Wizard PCR purifi- cation resin. The probe was radiolabeled to a specific activity of 1.0 × 10 9 c.p.m./g using ␣-32 P-dCTP (3000 Ci/mmol) by random oligonucleotide primer extension (Multiprime DNA labeling system; Amersham Japan). The filters were hybridized at 42°C overnight in the presence of radiolabeled probes. Northern blots were washed twice with 2 × SSC containing 1.0% (w/v) SDS at room temperature, and once with 0.2 × SSC containing 0.1% (w/v) SDS. The dried filter was exposed to Kodak XAR film at −80°C for 24 h and developed.
Western blot analysis of EGR-1 after treatment with DAC
K562/ADM cells were treated with or without 5.0 m DAC for 4 days. Whole-cell lysates were denatured by 3 min boiling, fractionated on 8.0% SDS-polyacrylamide gel and transferred to nitrocellulose membranes. The blots were blocked with 50 mmol/l Tris-HCl, pH 8.0, 150 mmol/l NaCl, 5% non-fat milk and 0.3% Tween 20 at room temperature for 30 min and incubated in the same buffer containing anti-EGR-1 antibody at 4°C overnight. The immunoblots were visualized with an enhanced chemiluminescence system (ECL; Amersham Life Science Technology) after incubation with horseradish peroxidase conjugated anti-rabbit antibody.
Results

The -110 GC-box of the MDR-1 gene is methylated in K562/ADM, but not parental K562 cells
Within the promoter region of the MDR-1 gene, we focused on the -110 and -50 GC-boxes because the GC-box is widely considered to be important in the TATA-less promoter. Upon modification with sodium bisulfite, all cytosines should be converted to uracil, whereas methylated cytosine (5-methylcytosine) is resistant to this modification and remains in the original state. Taking advantage of this feature, we obtained detailed information about the methylation status of all 28 CpG sites within the amplified region including the -110 GC-box and the -50 GC-box. Figure 1 shows a representative sequence analysis of the -110 and -50 GC-boxes after sodium bisulfite treatment of K562/ADM cells. Among 20 DNA clones from K562/ADM cells, four clones were methylation-positive at the both GC-boxes. In addition, all other CpG sites in these same four clones were methylated. The rest of 16 clones were methylation-negative at all 28 CpG sites including both GC-boxes. In contrast, in parental K562 cells, two clones were methylation-positive and 18 were negative Representative DNA sequence of methylated and unmethylated alleles in K562/ADM cells. MDR-1 promoter region (left: -50-GC box, right: -110 GC-box) is amplified and applied to sequence analysis. The MDR-1 promoter sequence from GenBank is shown at the top of each figure. Cytosines which are methylated (asterisk) remain as cytosines after sodium bisulfite treatment (upper panel), while unmethylated cytosines are converted to thymidines (lower panel). The experimental procedure is described in Materials and methods.
at the -50 GC-box, while all of the subcloned samples (20/20) were methylation-negative at the -110 GC-box (Table 1) . These two clones, which were methylation-positive at -50 GC-box and methylation-negative at -110 GC-box, were methylation-positive at all other CpG sites except at -263. Figure  2 shows MSP analysis of the -110 GC and -50 GC-boxes in K562/ADM, parental K562 and normal bone marrow mononuclear cells. No methylation was detected at either the -50 or the -110 GC-box in normal bone marrow cells. We therefore defined 'methylation-positive by MSP' as 'hypermethylation'. Consistent with the results shown in Table 1 , the repressor binding site of the MDR-1 gene (-110 GC-box) was not methylated in parental K562 cells, but was hypermethylated in K562/ADM cells. These data suggest that P-gp expression may be related to the methylation status of the -110 GC-box.
Figure 2
Methylation-specific PCR of MDR-1 (left: -50 GC-box, right: -110 GC-box). Primer sets are designed to amplify methylated (M) and unmethylated (U) alleles.
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DAC treatment suppresses P-gp expression in K562/ADM cells
If hypermethylation at the -110 GC-box prohibits the binding of repressor molecules in K562/ADM cells, P-gp expression should be suppressed by treatment with DAC, an inhibitor of DNA methyltransferase. We monitored changes in P-gp expression after DAC treatment in K562/ADM cells. Figure 3 shows flow cytometric analysis results of K562/ADM cells with and without 4 days of DAC treatment. P-gp expression in these cells was clearly suppressed by DAC treatment. Northern blot analysis also revealed MDR-1 expression to be suppressed after 4 days of DAC treatment. An approximately 65% decrease was observed, by densitometric scanning of the autoradiogram, as compared with the control sample (Figure 4a ). We also studied the time-course of MDR-1 expression in DACtreated K562/ADM cells. As shown in Figure 4b , the suppression of MDR-1 by DAC had already become apparent at 8 h incubation, with an approximately 70% decrease by densitometric scanning. We also confirmed demethylation at the -50 and -110 GC-boxes after DAC treatment in K562/ADM cells, employing a MSP technique (Figure 4c ).
EGR-1 expression is not changed by DAC treatment in K562/ADM cells
EGR-1 has been shown to act as a transcriptional activator in MDR-1 gene regulation. As DAC may suppress P-gp expression through down-regulation of EGR-1, we studied EGR-1 expression in K562/ADM cells with or without DAC treatment. As shown in Figure 5 , expression of EGR-1 did not change after DAC treatment of K562/ADM cells (lanes 2 and 3) .
Discussion
Multidrug resistance is often induced by repeated chemotherapy in patients with hematological malignancies. The MDR-1 gene encodes P-gp, one of the factors responsible for the induction of multidrug resistance. However, MDR-1 gene regulation is not yet fully understood. The GC-box has generally been thought to be a key factor in the TATA-less promoter. In addition, DNA methylation at the CpG island of the promoter region is known to play an important role in regulating gene expression. De novo methylation has been shown to be associated with transcriptional silencing of tumor suppressor genes, including p15, p16 and Rb, and is also involved in X-chromosome inactivation and genomic imprinting. 13, [18] [19] [20] [21] [22] Gene expression is reportedly upregulated by DAC treatment in many genes including p15, p16 and Rb. In contrast, 1-4) . Another primer pair, which was used to amplify the region including -110 and -50 GC-boxes (Material and methods), was also used for demonstrating the amount of DNA (lanes 5 and 6). This primer set does not contain CpG sites, and thus, is free from DAC effects. The amounts of PCR-products representing the -50 GC-box and the -110 GC-box are both decreased in DAC treatment, while the amount of DNA used was slightly greater in DAC treatment in this particular experiment. DAC induced down-regulation of MDR-1 gene expression in K562/ADM cells. The different responses to DAC can be explained as follows. Methylation status is reportedly related to the expression of the genes including p15, p16 and Rb. In these genes, each transcript is down-regulated when hypermethylation occurs at the promoter region. Therefore, the expression of these genes is increased by DAC treatment. In the MDR-1 gene, however, the -110 GC-box is known to be a transcriptional repressor binding site. The MDR-1 promoter activity was shown to be increased six-fold when this site was mutated. 5 We herein demonstrated the -110 GC-box of the MDR-1 gene to be methylated in K562/ADM but not parental K562 cells. Therefore, P-gp expression was down-regulated by DAC treatment in K562/ADM cells, possibly due to demethylation at the repressor binding site.
The -50 GC-box is an activator-binding site in the MDR-1 gene promoter. Transcriptional factors, including SP-1 and EGR-1, bind to the -50 GC-box. Cytosine methylation reportedly does not affect transcriptional factor SP-1 binding to the human metallothionein IIA promoter. 23 As for EGR-1, McCoy et al reported this transcriptional factor to be necessary for MDR-1 promoter activity in response to 12-o-tetradecanoylphorbol-13-acetate (TPA) in K562, and that EGR-1 effectively induced reporter gene activity through binding to the MDR-1 promoter encompassing the SP-1/EGR-1 site, which corresponds to the -50 GC-box. 6 However, DAC treatment did not change EGR-1 expression in K562/ADM cells, indicating that EGR-1 levels are not involved in changes in MDR-1 gene expression after DAC treatment.
Kantharidis et al 24 reported that DAC treatment increased P-gp in a human T cell leukemia cell line. This is apparently in conflict with our present results. GC-boxes are not always a primary regulator for MDR-1 regulation. For example, NF-IL6 binding site was shown to be more important than GCboxes in MDR-1 regulation in HTLV-1 infected cell lines. 25 Furthermore, Fryxell et al 26 described the methylation status of the CpG-rich domain as not acting as a switch regulating MDR-1 gene expression. Intracellular levels of various transcriptional factors may vary in cells, which may explain these conflicting results. Although promoter region methylation status may not be the only factor regulating MDR-1 gene expression, the present results suggest that the methylation status of the -110 GC-box, the repressor binding site, regulates MDR-1 gene expression in K562/ADM cells.
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